UCB and Biogen’s dapirolizumab pegol paves path for systemic lupus erythematosus treatment GlobalData Nov 13, 2024 With a novel CD40L-targeting mechanism and favourable efficacy outcomes, this therapy has the potential to challenge established…
UCB and Biogen’s dapirolizumab pegol paves path for systemic lupus erythematosus treatment GlobalData Oct 13, 2024 With a novel CD40L-targeting mechanism and favourable efficacy outcomes, this therapy has the potential to challenge established…
